Portola Pharma (PTLA) to Present Results from Betrixaban Phase 3 APEX Study at AHA Scientific Sessions
- Goldman sends Dow to record high, techs lift S&P, Nasdaq
- Oil hits 16-month high in buying rush after OPEC agreement
- Consolidated Communications (CNSL) to Acquire FairPoint Communications (FRP) in $1.5B Deal
- Pre-Open Stock Movers 12/05: (FRP) (GMED) (CHK) Higher; (CERC) (HDSN) (MRVL) Lower (more...)
- Burberry rejects multiple takeover offers from Coach: Financial Times
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Portola Pharmaceuticals Inc.® (Nasdaq: PTLA) announced that results of new sub-analyses of the Phase 3 APEX Study of betrixaban, conducted by Dr. C. Michael Gibson and the PERFUSE Study Group, will be presented in oral and poster sessions at the upcoming American Heart Association (AHA) Scientific Sessions 2016, which is taking place from November 12-16 in New Orleans.
Betrixaban, a U.S. Food and Drug Administration (FDA) Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant in development for the prevention of venous thromboembolism (VTE) in acute medically ill patients. Portola submitted a New Drug Application to the FDA in October 2016 seeking approval to market betrixaban for extended-duration prophylaxis of VTE in acute medically ill patients with risk factors for VTE. Portola expects a response from the FDA within 60 days as to whether the NDA is complete and acceptable for filing.
Following are details of the oral and poster presentations, which will include additional data not available in the abstracts. AHA will post the abstracts on Friday, November 11, at 4:00 p.m. ET at http://www.abstractsonline.com/pp8/#!/4096.
- Abstract Title: Betrixaban reduces the burden of multiple symptomatic venous thromboembolic events in the APEX trial
Abstract #: 640Presenting Author: Purva Jain, M.P.H., biostatistician, PERFUSE Study Group, Beth Israel Deaconess Medical Center, BostonSession Title: Hemostasis, Thrombosis and FibrinolysisPresentation Date and Time: Monday, November 14, 10:30 -10:35 a.m. CT Presentation Location: Science and Technology Hall, Basic Science Theater
- Abstract Title: Extended duration betrixaban reduces the risk of stroke vs standard dose enoxaparin among hospitalized medically ill patients: An APEX substudy
Abstract #: 277Presenting Author: C. Michael Gibson, M.S., M.D., APEX Executive Committee Member and Steering Committee Chairman; professor, Harvard Medical School; chairman, PERFUSE Study Group, Beth Israel Deaconess Medical Center, BostonSession Title: Sol Sherry Distinguished Lecture in ThrombosisPresentation Date and Time: Monday, November 14, 3:15-3:25 p.m. CTPresentation Location: Room 217
- Abstract Title: IMPROVEDD Score: Addition of D-dimer to the IMPROVE score improves venous thromboembolism risk stratification: An APEX trial substudy
Abstract #: T1201/1201Presenting Author: Gerald Chi, M.D., PERFUSE Study Group, Beth Israel Deaconess Medical Center, BostonSession Title: Hemostasis, Thrombosis and FibrinolysisPresentation Date and Time: Tuesday, November 15, 12:45-2:00 p.m. CTPresentation Location: Science and Technology Hall, Basic Science Section
About the APEX Study
The pivotal Phase 3 APEX Study enrolled 7,513 patients at more than 450 clinical sites worldwide and assessed the superiority of extended-duration anticoagulation with oral betrixaban for 35-42 days compared with standard-duration injectable enoxaparin for 10+4 days in preventing VTE in high-risk acute medically ill patients. Full study results were presented at the 62nd Annual International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC) Meeting in May 2016 and published simultaneously online in The New England Journal of Medicine.
About BetrixabanBetrixaban, an investigational drug, directly inhibits the activity of Factor Xa, an important validated target in the blood coagulation pathway, to prevent life-threatening thrombosis. Betrixaban has distinct properties that may allow it to demonstrate clinical benefit without the significant imbalance in the risk of major bleeding seen with other agents in the class. These include a 19-25-hour half-life for once-daily dosing; a low peak-to-trough drug concentration ratio that minimizes anticoagulant variability; low renal clearance; and no significant CYP3A4 metabolism, which may reduce the risk of drug-drug interactions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotheby's (BID) Acquires Orion Analytical, Names James Martin as Director of Scientific Research
- General Mills (GIS) to Form New Organizational Structure; Will Focus on Four Business Groups
- Zynerba Pharma (ZYNE) Announces Strong ZYN002 Phase 1 in Epilepsy Patients with Focal Seizues
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!